The ASCO Genitourinary (GU) Cancers Symposium, which ended on February 18, 2023, was a three-day scientific and educational meeting designed to provide attendees with in-depth, multidisciplinary analysis of the timely topics in the study, diagnosis, and treatment of GU malignancies. DelveInsight has compiled the symposium’s major highlights so that one does not miss out on these expansions in GU malignancies, with a special focus on Prostate and Urothelial Cancer.
Major Pharma companies involved in presenting their Prostate and Urothelial cancer data readouts during the recent ASCO Genitourinary (GU) Cancers Symposium include BMS, Pfizer, Bayer, Janssen, AstraZenec...
